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Background: Niemann-Pick type C1 disease (NPC1) is a rare progressive neurodegenerative disorder caused by
mutations in the NPC1 gene. In this lysosomal storage disorder the intracellular transport and sequestration of
several lipids like cholesterol is severely impaired, resulting in an accumulation of lipids in late endosomes and
lysosomes. The neurological manifestation of the disease is caused by dysfunction and cell death in the central
nervous system. Several animal models were used to analyze the impaired pathways. However, the underlying
pathogenic mechanisms are still not completely understood and the genetic variability in humans cannot be
reflected in these models. Therefore, a human model using patient-specific induced pluripotent stem cells provides
a promising approach.
Methods: We reprogrammed human fibroblasts from a NPC1 patient and a healthy control by retroviral
transduction with Oct4, Klf4, Sox2 and c-Myc. The obtained human induced pluripotent stem cells (hiPSCs) were
characterized by immunocytochemical analyses. Neural progenitor cells were generated and patch clamp
recordings were performed for a functional analysis of derived neuronal cells. Filipin stainings and the Amplex Red
assay were used to demonstrate and quantify cholesterol accumulation.
Results: The hiPSCs expressed different stem cell markers, e.g. Nanog, Tra-1-81 and SSEA4. Using the embryoid
body assay, the cells were differentiated in cells of all three germ layers and induced teratoma in immunodeficient
mice, demonstrating their pluripotency. In addition, neural progenitor cells were derived and differentiated into
functional neuronal cells. Patch clamp recordings revealed voltage dependent channels, spontaneous action
potentials and postsynaptic currents. The accumulation of cholesterol in different tissues is the main hallmark of
NPC1. In this study we found an accumulation of cholesterol in fibroblasts of a NPC1 patient, derived hiPSCs, and
neural progenitor cells, but not in cells derived from fibroblasts of a healthy individual. These findings were
quantified by the Amplex Red assay, demonstrating a significantly elevated cholesterol level in cells derived from
fibroblasts of a NPC1 patient.
Conclusions: We generated a neuronal model based on induced pluripotent stem cells derived from patient
fibroblasts, providing a human in vitro model to study the pathogenic mechanisms of NPC1 disease.
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Human induced pluripotent stem cells (hiPSCs) feature
three major advantages in the field of stem cell research.
First, cells can be obtained by reprogramming different
somatic cells [1-4] without raising ethical concerns, as it
is the case with embryonic stem cells. Second, the pluri-
potent potential of the cells offers the opportunity to dif-
ferentiate them into each cell of the body, e.g. motor
neurons [5], cardiomyocytes [6], pancreatic insulin-
producing cells [7], or male germ cells [8]. Third, iPS
cells and subsequently differentiated cells have the same
genetic information as the donor cells. Different diseases
have already been modeled by using human iPS cells,
e.g. Parkinson disease [9], metabolic liver disorders [10],
retinal degeneration [11], Huntington disease [12], and
mucopolysaccharidosis type IIIB, a fatal lysosomal stor-
age disorder [13], and have been successfully utilized e.g.
in drug screening [14].
Taken together, these characteristics of the cells are
excellent prerequisites to model diseases in vitro. How-
ever, no in vitro model for Niemann-Pick disease Type
C1 (NPC1) based on hiPS cells is currently available.
NPC1 is a rare progressive neurodegenerative disease
caused by mutations in the NPC1 gene located on chro-
mosome 18q11 encoding for a 1278-amino acid intracel-
lular membrane glycoprotein [15-17]. It is inherited in
an autosomal recessive manner and shows a prevalence
of 1:120.000 live births [18]. A mutation in the NPC1
gene leads to an impaired lipid transport and sequestra-
tion resulting in e.g. a cholesterol accumulation in the
late endosome and lysosome [19]. The clinical manifes-
tation varies from neonatal icterus and hepatospleno-
megaly in early childhood, cerebellar ataxia, seizures,
gelastic cataplexy, and vertical supranuclear palsy in ado-
lescence, to progressive neurological degradation, psych-
oses, and dementia in adulthood [18]. The symptoms
are diverse and show intrafamilial variability [18,20].
The pathogenic mechanisms ultimately leading to a
massive degeneration and loss of neurons in the CNS,
especially Purkinje cells in the cerebellum, are not exact-
ly understood. Most of our knowledge regarding NPC1
is based on cell models like human fibroblasts [21-23]
and animal models like mouse [24], cat [25], and fruit fly
[26]. Studies using these models have neither revealed
the mechanisms leading to the selective massive de-
generation of neurons nor found drugs, which can effi-
ciently halt disease progression. Although the function
of NPC1 in lipid trafficking is evolutionary highly con-
served [27], the widely used murine BALB/c NPC1
model [28] cannot exactly reproduce human pathology.
For example, neurofibrillary tangles composed of tau
protein, which are seen in human NPC1 neurons, are
absent in this model reflecting obvious biochemical and
physiological differences [29]. Thus, studies utilizingdisease-specific human neurons hold great promise to
significantly increase our knowledge in understanding
the pathological mechanism leading to massive neuronal
degeneration. Recently, a human neuronal NPC1 model
was reported based on multipotent adult stem cells [30].
In our study, we generated patient-specific induced
pluripotent stem cells from a NPC1 patient and a healthy
individual. The hiPS cell lines were differentiated into
neural progenitor cells and subsequently differentiated




Human dermal fibroblast cell lines GM18436 and
GM05659 (Coriell Institute for Medical Research,
Camden, USA) were obtained by skin biopsies from
one-year old male Caucasian donors. GM18436 exhibits
compound heterozygous mutations in the NPC1 gene
(c.1628delC and GLU612ASP), representing a frameshift
mutation and a missense mutation, respectively. The
mutations lead to a non-functional protein as demon-
strated by cholesterol esterification assay [31]. Fibroblast
cell line GM05659 is obtained from a healthy donor. In
the following cells of the cell line GM18436 will be
referred to as mutNPC1 and cells of the cell line
GM05659 will be referred to as wtNPC1. Cells were cul-
tivated in fibroblast medium containing DMEM high
glucose, 10% FBS and 1% Penicillin/ Streptomycin.
Mitotically inactivated mouse embryonic fibroblasts
(GlobalStem, Rockville, USA) were used as the feeder
cell layer for hiPSCs. Cells were plated in fibroblast
medium at a density of 33.000 cells/ cm2 onto 0.1% gel-
atine coated wells in fibroblast medium 24 h before hiPS
cell split. HiPS cells were cultured on a feeder cell layer
in iPS medium containing DMEM/ F12, 20% knock-
out serum replacement, 1% Penicillin/ Streptomycin,
1% GlutaMAX, 1% MEM non essential amino acids,
0.2% 2-mercaptoethanol, and 10 to 15 ng/ ml hFGF-2
(Globalstem, Rockeville, USA). hiPS cells on matrigel
(BD Biosciences, Heidelberg, Germany) were cultured in
mTESR1 medium (Stemcell Technologies, Grenoble,
France). Medium was changed daily and cells were pas-
saged weekly using 10 μM ROCK inhibitor Y-27632
(Stemgent, Cambridge, USA) for increased plating effi-
ciency. HiPS cells growing on a feeder cell layer were
split mechanically weekly using pulled glass hooks by
performing the cut and paste technique. Cells growing
on matrigel were harvested enzymatically using 1 mg/
ml dispase (Stemcell Technologies, Grenoble, France)
for 7 min and large bore tips to break down large
clumps according to manufacturer’s recommendations.
HEK293FT cells (Invitrogen, Darmstadt, Gemany) used
to obtain the viral vectors were cultivated in fibroblast
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cultivated at 37°C in a saturated humidity atmosphere
containing 5% CO2.
Generation of retroviruses
Retroviral pMIG vectors containing the cDNA of the
human genes Oct4, Sox2, Klf4, and c-Myc were used as
described recently [32]. Briefly, 3×106 HEK293FT cells
per 10 cm-dish were seeded onto ten dishes and incu-
bated overnight. A solution containing 2.5 μg retroviral
vector encoding for GFP and one of the transcription
factors (Sox2, Klf4, Oct4, or c-Myc) was incubated with
0.25 μg VSV-G and 2.25 μg Gag-Pol in X-tremeGENE9
(Roche, Mannheim, Germany)/ DMEM High Glucose
mixture (1:4) which was added to each of the dishes.
Medium was renewed after 18 h and cells were in-
cubated further for 48 h. Subsequently, the virus-
containing medium was collected and passed through a
0.45 μm filter. To concentrate the virus, the medium
was centrifuged at 70.000 × g at 4°C for 90 min,
resuspended in 0.1 to 1 ml DMEM medium, and stored
at −80°C. All four vectors contained a GFP sequence
thus enabling titering by determining the percentage of
GFP positive HEK293FT cells using FACS. Therefore,
1×105 HEK293FT cells were seeded per 12-well in
Penicillin/ Streptomycin free fibroblast medium con-
taining 5 μg/ ml protamine sulfate and concentrated
virus in the following volumes: 6.25 μl, 12.5 μl, 25 μl,
and 50 μl. After 48 h cells were washed with PBS
containing Ca2+/ Mg2+, trypsinized and centrifuged for
5 min at 500 × g. Pellet was resuspended in 100 μl
PBS without Ca2+/ Mg2+ and fixed by adding 100 μl
of 4% paraformaldehyde for 15 min. Afterwards, the
percentage of GFP positive cells was determined via
FACS analysis.
Transduction of human fibroblasts
For transduction, 1×105 fibroblasts were seeded per cav-
ity of a 6-well plate and cultured for 18 h in fibroblast
medium without Penicillin/ Streptomycin. Afterwards,
fibroblast medium without Penicillin/ Streptomycin was
supplemented with a volume of retrovirus of Sox2, Oct4,
Klf4 (corresponding to 70 – 80% infection efficiency),
and c-Myc (corresponding to 40–50% infection effi-
ciency) in the presence of 5 μg/ ml protamine sul-
fate. Cells were incubated for 48 h. Subsequently,
medium was aspirated and cells were washed twice
with PBS containing Ca2+/ Mg2+. Transduced cells
were trypsinized and reseeded onto a gelatin coated
6 cm-dish. The next day, medium was replaced with
iPS medium supplemented with 0.5 mM valproic acid
to further increase the efficiency of reprogramming.
Medium was changed daily and valproic acid was
omitted after seven days.Generation of hiPS cell lines
Initial hiPS colonies were routinely observed after three
to four weeks. For further cultivation, they were picked
using a 100 μl pipette tip and a pulled glass hook. Single
colonies were transferred to the cavities of a 24-well
plate, coated with 0.1% gelatin and 45.000 feeder
cells/ cm2. After 4 to 7 days of proliferation hiPS col-
onies were mechanically divided into two to four pieces
and further expanded. Within six weeks each single hiPS
colony was expanded to obtain different clones.
Karyotyping
Karyotyping was performed by Giemsa Trypsin banding.
In short, colonies were incubated with a colcemid solu-
tion (10 μg/ ml in HBSS) for three hours to arrest cells
in metaphase. Cells were treated with trypsin (0.25%)
and the enzymatic reaction was stopped with Amniomax
solution (Invitrogen, Darmstadt, Germany). Cells were
centrifuged at 300 × g for 10 min and the pellet was
resuspended in 4 ml hypotonic potassium chloride solu-
tion (5.62%). Cells were incubated for 5 min at 37°C and
centrifuged at 300 × g for 10 min. The cells were
resuspended and fixed in 5 ml glacial acetic acid and
methanol (1:3) and subsequently centrifuged for 7 min
at 350 × g. This step was repeated once. Finally, most of
the supernatant was removed and cells were resus-
pended. Cell suspension was dropped onto cold slides
and dried at 100°C for 1 h. Giemsa solution (5%) was
added and incubated for 5 min. Slides were washed in
distilled water two times, dried at room temperature and
sealed with cover slips.
Sequencing
Genomic DNA of fibroblasts, iPS cells grown on ma-
trigel or neural progenitor cells were isolated using
AllPrep Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s recommendations. Exon regions were
amplified using HotStart Taq (Qiagen, Hilden, Germany)
as follows: 95°C for 15 min followed by 13 cycles of 94°C
for 30 s, 66°C for 30 s with 1.5°C decrease/ cycle and
72°C for 20 s; followed by 8 cycles of 94°C for 30 s,
46.5°C for 30 s with 1°C increase/ cycle and 72°C for
20 s; followed by 13 cycles of 94°C for 30 s, 66°C for
30 s with 1.5°C decrease/ cycle and 72°C for 20 s;
followed by 11 cycles of 94°C for 30 s, 54.5°C for 30 s
with 1°C increase/ cycle and 72°C for 20 s. Products were
purified using ExoSAP Kit (USB Europe GmbH, Staufen,
Germany) according to manufacturer’s recommendations.
Sequence analysis was performed on a 3130XL Genetic
Analyzer (Applied Biosystems, Carlsbad, USA).
Alkaline phosphatase staining
HiPSCs were cultivated on a feeder cell layer for five
days. Medium was removed, cells were washed with PBS
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at −20°C. Methanol was removed and cells were washed
with PBS. Subsequently, cells were incubated at room
temperature for 15 min with the staining solution: 75%
distilled water, 10% sodium chloride solution (1 M), 10%
Tris solution (1 M, pH 9.8), 5% magnesium chloride so-
lution (1 M), and NBT/ BCIP solution (1:50, Roche,
Mannheim, Germany). Staining solution was removed
and cells were washed with distilled water. Microphoto-
graphs were taken using a Nikon Eclipse TS100 (Nikon,
Düsseldorf, Germany).
Immunocytochemistry
Cells were fixed at room temperature for 15 minutes in
4% paraformaldehyde, washed with PBS and stored in
0.02% NaN3 at 4°C. Immunocytochemistry was perfor-
med for Nanog (1:100, rabbit IgG polyclonal), Oct4
(1:100, rabbit IgG polyclonal), SSEA3 (1:100, rat IgM),
SSEA4 (1:100, mouse IgG3), Tra-1-60 (1:100, mouse
IgM), Tra-1-81 (1:100, mouse IgM, all Stemgent,
Cambridge, USA), Smooth muscle actin (SMA, 1:50,
mouse monoclonal, Dako, Glostrup, Denmark), alpha fe-
toprotein (alpha FP, 1:500, mouse monoclonal IgG, Sigma-
Aldrich, Hamburg, Germany), Nestin (1:100, mouse
monoclonal, R&D, Wiesbaden, Germany), MAP2ab
(1:100, mouse monoclonal, Chemicon, Schwalbach,
Gemany), Tuj1 (1:100, mouse monoclonal Tu-20,
Santa Cruz biotechnology, Heidelberg, Germany) and
Sox-2 (1:200, rabbit monoclonal, Abcam, Cambridge,
UK). Blocking and permeabilization was carried out
using 0.3% Triton X-100 and 5% normal goat serum
(Dako, Glostrup, Denmark) for 30 min at room
temperature. Cells were incubated with primary anti-
bodies for 3 hours at room temperature in 1% nor-
mal goat serum, followed by three washing steps with
PBS. Alexa Fluor 568 (1:1000, goat anti-mouse IgG or
goat anti-rabbit IgG, Invitrogen, Darmstadt, Germany),
Alexa Fluor 488 (1:1000, goat anti-mouse IgG or goat
anti-rabbit IgG, Invitrogen, Darmstadt, Germany), or
Alexa Fluor 488 (1:1000, goat anti-mouse IgM or goat
anti-rat IgM, Invitrogen, Darmstadt, Germany) were used
as secondary antibodies, incubated 1 h at room tem-
perature with 1% normal goat serum in PBS. After wa-
shing with PBS, cells were stained with DAPI (5 minutes,
250 ng/ ml), washed three times and mounted with
Mowiol-DABCO mounting medium. Pictures were taken
with a Biozero 8000 microscope system (Keyence,
Hamburg, Germany).
Generation of embryoid bodies
To generate embryoid bodies (EBs), whole hiPS colonies
were mechanically lifted off the feeder cell layer and
transferred into a 15 ml conical tube. Once the colonies
settled at the bottom of the conical tube, the mediumwas removed and 5 ml of differentiation medium, con-
taining knockout DMEM, 20% FBS, 1% MEM non-
essential amino acids, 2 mM GlutaMAX, and 0.1 mM
beta-mercaptoethanol, was added. Afterwards, colonies
were transferred into the cavity of a low attachment
6-well plate and incubated at 37°C/ 5% CO2. Medium
was changed every second day until EBs were formed.
After five to seven days EBs were transferred onto gel-
atin coated glass cover slips and supplied with differenti-
ation medium. Once EBs were attached, medium was
changed every second or third day. After 10 days of ran-
dom differentiation, spread cells were washed with PBS
and fixed with 4% PFA for 15 min. Fixed cells were
washed with PBS and immunocytochemical stainings for
nestin (ectoderm), smooth muscle actin (mesoderm),
and alpha-fetoprotein (endoderm) were performed.
Teratoma formation assay
Immunodeficient (SCID) hairless mice (Charles River
Laboratories, Sulzfeld, Germany) were used for the tera-
toma formation assay. HiPSCs for injection were cul-
tured on feeder cells in 6-well culture plates. For each
injection the amount of 3 cavities of a 6-well culture
plate were collected mechanically and centrifuged for 2
min at 200 × g. The pellet was resuspended in 1 ml of
0.25% trypsin/ EDTA. After 1 min, the reaction was
stopped by adding 2 ml of fibroblast medium and
centrifuged again for 2 min at 200 × g. Cells were
resuspended in 140 μl of cold DMEM/ F12 and stored
on ice. Directly before injection, cell suspension was
mixed with 60 μl matrigel. Cells were injected subcuta-
neously into the flank of the hind limb. After 8–12
weeks, when tumors were clearly visible, the animals
were sacrificed and tumors were removed. Tumor tissue
was fixed in 4% formalin for 12 to 18 hours and embed-
ded in paraffin for subsequent staining.
H&E staining of tumor sections
4 μm thick tumor tissue sections were deparaffinized in
xylol for 10 min and a descending ethanol concentration
for 5 min each. Afterwards, the sections were washed in
distilled water and stained with Mayers hematoxylin
(Merck, Darmstadt, Germany) for 1 min. Next, the tis-
sue was washed two times in distilled water and stained
with eosin Y (Sigma-Aldrich, Hamburg, Germany) for 2
min. The slides were washed again twice and then
dehydrated using an ascending ethanol concentrattion
and xylol. Slides were mounted in Mowiol-DABCO. Mi-
crophotographs were taken with a Biozero 8000 micro-
scope system (Keyence, Hamburg, Germany).
Neural differentiation
To differentiate hiPS colonies into neural direction,
the colonies were cut, transferred to Poly-L-ornithine
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cultivated for 10 days in medium consisting of Neuro-
basal, DMEM/ F12, 1xN2 supplement, 1xB27 supplement,
GlutaMAX (2 mM) complemented with mouse recombi-
nant noggin Fc-chimera (500 ng/ ml, R&D, Wiesbaden,
Germany), SB431542 (20 μM, Sigma-Aldrich, Hamburg,
Germany) and hFGF-2 (5 ng/ ml, GlobalStem, Rockeville,
USA). Neural rosettes were manually isolated using pulled
glass hooks, gently trypsinized, and seeded as single cells
on Poly-L-ornithine/ laminin coated dishes in medium
consisting of Neurobasal, DMEM/ F12, 1×N2, 1×B27,
and GlutaMAX (2 mM) supplemented with hFGF-2
(10 ng/ ml) and hEGF (10 ng/ ml, Peprotech, Hamburg,
Germany). Neural progenitor cells were seeded at high
densities (100–150.000 cells/ cm2) and passaged one day
after reaching confluence using Trypsin/ Benzonase. Dif-
ferentiation was induced by seeding the cells at a density
of 50.000 cells/ cm2 and withdrawal of growth factors in
the presence of BDNF (20 ng/ ml, Peprotech, Hamburg,
Germany).
Patch clamp recordings
Patch clamp recordings were performed using an EPC-
10 amplifier (Heka, Lambrecht, Germany). Patch pipet-
tes were pulled from borosilicate glass tubing (Harvard
Apparatus, Holliston, USA). The internal solution con-
tained (mM): KCl 130, NaCl 10, HEPES 10, EGTA 11,
MgCl2×6H2O 1, CaCl2×H2O 2, Mg-ATP 2. pH was ad-
justed to 7.2. When filled, electrodes had a resistance of
6–8 MΩ. Cell cultures were continuously superfused
with an extracellular solution, consisting of (mM): NaCl
125, KCl 2.5, CaCl2×H2O 2, MgCl2×6H2O 1, NaHCO3
26, NaH2PO4×H2O 1.25, glucose×H2O 25. Solution was
continuously bubbled with carbogen to maintain a pH of
7.4. Recordings were made in the whole cell configu-
ration with holding potentials (VH) of −60 or −80 mV.
Current voltage responses were evoked by applying 100
ms voltage steps from −60 mV to +50 mV in 10 mV in-
crements. Data were filtered at 3 kHz, digitized and
stored on-line using Pulse (Heka, Lambrecht, Germany).
Na+ and K+ currents were identified via their I-V rela-
tionship. Na+ currents were antagonized in some experi-
ments by TTX (1 μM). Current clamp mode was used to
apply current steps to induce action potentials or to
measure spontaneous action potentials. Postsynaptic
currents were measured in the voltage clamp mode at a
VH of −60 mV. Mini Analysis 6 (Synaptosoft, USA) was
used to analyse recordings of post-synaptic currents.
Data are given as mean ± SEM.
Filipin staining
Filipin is a polyene antibiotic which binds to free choles-
terol and is widely used to analyze the sequestration of
unesterified cholesterol in NPC1-deficient cells. Therefore,cells were fixed with 4% paraformaldehyde (in PBS) for 15
min, washed with PBS and incubated at room temperature
for 45 min in the dark with a staining solution containing
100 μg/ ml Filipin (Polysciences, Eppelheim, Germany) in
PBS. Cells were washed twice with PBS for 5 min. Slides
were mounted using Mowiol-DABCO and sealed with
cover slips. After 12 h of drying in the dark at room tem-
perature, fluorescence pictures were taken with a Biozero
8000 microscope (Keyence, Hamburg, Germany).
Amplex red assay
To quantify the amount of cholesterol we used the
Amplex Red cholesterol assay [33]. Fibroblasts, iPS cells
grown on matrigel and neural progenitor cells were
harvested in PBS/ SDS (0.1%) at room temperature,
sheared through a 27 G needle and cholesterol levels
were determined using the Amplex Red cholesterol assay
kit (Molecular Probes, Darmstadt, Gemany) according to
the manufacturer’s instructions. Protein concentrations
in lysates were measured using the bicinchoninic acid
assay (BCA, Pierce, USA).
Statistical analysis
Analysis of the data was carried out with GraphPad
Prism 5 (GraphPad Software Inc., USA). Data are given
as mean ± SEM. Unless otherwise stated, unpaired
t-tests were used to test for significance, with * = p<0.05
and ** = p<0.01, *** = p<0.001.
Results
Reprogramming of mutNPC1 and wtNPC1 fibroblasts
We reprogrammed fibroblasts originating from a male
patient with an early-infantile form of NPC1 character-
ized by massive accumulation of unesterified cholesterol
in lysosomal and late endosomal structures. Cells de-
rived from this donor will be referred to as mutNPC1
and cells derived from age- and sex-matched fibroblasts
of a healthy individual will be referred to as wtNPC1.
After three to four weeks of cultivation, the first hiPSC
colonies appeared characterized by their embryonic stem
(ES) cell-like morphology, e.g. round to oval shape with
a sharp border and a high nuclear to cytoplasm ratio
(Figure 1A-D). Mechanically isolated colonies were ex-
panded to hiPSC lines on irradiated mouse embryonic
fibroblasts and later also on matrigel (Figure 1C,D). The
morphology of mutNPC1 and wtNPC1 hiPSCs was
similar in both culture systems. The karyotype of the
cells was analyzed to rule out any chromosomal ab-
normalities, which may have arisen during reprogram-
ming, where our hiPSCs displayed a normal karyotype
(Figure 1E,F). Sequencing of the hiPSCs revealed that
the mutations in the NPC1 gene were maintained
(data not shown).
Figure 1 Colonies of fibroblast-derived human iPSCs. Images of hiPSC colonies cultured on mouse feeder cells (A,B) or matrigel (C,D).
The colonies could be easily distinguished by their morphology, showing a high nuclear to cytoplasm ratio and sharp borders, resembling the
morphology of human embryonic stem cells (scale bars = 100 μm). The hiPSCs-derived from fibroblasts of a NPC1-patient (E) and unaffected
individual (F) displayed a normal karyotype. Karyotyping was performed by Giemsa Trypsin banding.
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HiPSCs derived from of mutNPC1 and wtNPC1 human
fibroblasts were characterized regarding their pluripo-
tency. First, we analyzed the alkaline phosphatase (AP)
expression. All hiPSCs colonies demonstrated strong AP
expression (Figure 2A,B). The expression of several tran-
scription factors and surface markers was determined by
immunocytochemistry. HiPSCs displayed a high expres-
sion of the transcription factors Nanog (Figure 2C,D)
and Oct4 (Figure 2E,F). The glycosphingolipids SSEA3
and SSEA4 (Figure 2G-J), were strongly expressed as
well as the keratan sulfate antigens Tra-1-60 and Tra-
1-81 (Figure 2K-N). No obvious differences between
mutNPC1 and wtNPC1 cells in marker expression could
be observed. The spontaneous differentiation by embryoid
body (EB) formation into cells of all three germ layers was
also used to verify the pluripotency (Figure 3A-H). Herein,
cells from all three germ layers were identified, thus prov-
ing the pluripotency of the hiPSCs in vitro. The inductionof teratoma was used as an in vivo pluripotency assay. The
hiPSCs induced teratomas in immunodeficent mice, and
the analysis of the tumors revealed tissues of all three
germ layers (Figure 3I-N).
Neuronal differentiation of mutNPC1 and wtNPC1 hiPS
cells
In a last step, we generated neural progenitor cells, which
were positive for Nestin and Sox2 (Figure 4A,B,E,F).
Differentiated neural progenitor cells expressed neu-
ronal markers like MAP2 (Figure 4C,G), and Tuj1
(Figure 4D,H) demonstrating the neuronal phenotype
of the cells. Furthermore, we proved the differentiation
into functional neuronal cells by means of patch clamp
recordings. In these experiments we observed voltage
dependent Na+ and K+ channels (NaVs and KVs) (Figure 4I)
after three to four weeks of differentiation, where inward
currents could be blocked by TTX (Figure 4K). Although
the cells exhibited NaVs, they did not demonstrate any
Figure 2 Detection of pluripotency markers in hiPSCs.
hiPSCs-derived from fibroblasts of NPC1 patient (mutNPC1) and
unaffected control (wtNPC1) showed a strong alkaline phosphatase
(AP) staining (A,B) and expressed a set of pluripotency markers
(C-N) demonstrating the pluripotent state of the cells (scale
bars = 100 μm).
Figure 3 Embryoid body formation and teratoma induction.
Free floating embryoid bodies (EBs) of mutNPC1 and wtNPC1 hiPSCs
were generated (A,B), which subsequently spontaneously
differentiated (C-H). EBs of both cell lines were positive for markers
of the three germ layers, namely Nestin (C,D) for ectoderm, smooth
muscle actin (SMA) for mesoderm (E,F), and alpha fetoprotein (alpha
FP) for endoderm (G,H). Nuclei were stained by DAPI, shown in
blue, staining of Nestin, SMA and alpha FP is shown in green (scale
bars A-H = 100 μm). HiPSCs of the mutNPC1 and wtNPC1 cell lines
were injected in immunodeficient mice and tumors were extracted
after 8–12 weeks. MutNPC1 and wtNPC1 hiPSCs induced teratomas
contained structures typical for the ectoderm (I,J), mesoderm (K,L),
and endoderm (M,N, scale bars I-N = 50 μm).
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Figure 4 Differentiation of neural progenitor cells. HiPSC cell lines were directed to neural progenitor cells (A,B,E,F) and subsequently
differentiated into neuronal cells. Neural progenitor cells expressed typical markers like Nestin (A,E, shown in red) or Sox2 (B,F shown in red).
Differentiation of neural progenitor cells was induced by withdrawal of growth factors and resulted in cells demonstrating a neuronal
morphology, expressing neuronal markers like MAP2 (C,G shown in green) and Tuj1 (D,H shown in red). Inset in C and D shows an example of a
higher magnification to demonstrate the dense network of processes built up by the cells during differentiation. Patch clamp experiments were
performed to analyze the maturation of the cells into functional neuronal cells. Voltage steps elicited inward and outward directed Na+ and K+
currents (I), where Na+ currents could be blocked by TTX (J) and possessed I/ V relationship typical for voltage gated Na+ channels (K). The
example shows recordings of a mutNPC1 cell, differentiated for four weeks. After 7–9 weeks of differentiation, we observed spontaneous action
potentials (L) as well as spontaneous postsynaptic currents (M). (N) shows a superimposed average of spontaneous postsynaptic currents with
fast decay kinetics (red trace) and slow decay kinetics (black trace), indicating input of different synaptic sites. The example shows recordings of a
mutNPC1 cell, differentiated for 7 weeks.
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But, we observed spontaneous action potentials after 7–8
weeks of differentiation (Figure 4L). In addition, we re-
corded spontaneous postsynaptic currents. An example of
a mutNPC1 cell is shown in Figure 4M. The analysis ofthe decay kinetics (Figure 4N) revealed a rise time of 2.1 ±
1.1 ms. Analysing the decay kinetics we found a group of
post synaptic currents best fitted by a mono-exponential
function (τ: 3.5 ± 0.4 ms, Figure 4N, black trace) with a
mean amplitude of 29.5 ± 1.1 pA, and a group best fitted
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23.8 ms, Figure 4N, red trace) with a mean amplitude of
68.1 ± 7.1 pA.
mutNPC1 cells accumulated cholesterol
The hallmark of NPC1 is abnormal cholesterol traffick-
ing resulting in an accumulation of cholesterol. Free
cholesterol can be visualized by Filipin. An analysis of
the cholesterol distribution in mutNPC1 fibroblasts,
iPSCs, and derived neural progenitor cells (Figure 5A,C,E)
revealed an accumulation of cholesterol. In contrast, an
accumulation was not detectable in the fibroblasts, iPSCs,
or neural progenitor cells of the wtNPC1 counterpartFigure 5 Cholesterol accumulation in fibroblasts, hiPSCs, and neural p
NPC1 disease. Filipin stainings of fibroblast (A,B, shown in blue) are used fo
biochemical phenotype demonstrate a clear perinuclear accumulation (A)
differences were found in hiPSCs (C,D) and neural progenitor cells (hNPCs, E,
A quantification of the amount of cholesterol (G) in fibroblasts, iPSCs, and hN
in contrast to wtNPC1 cell lines (white bars). The total amount differed slightly(Figure 5B,D,F). As a next step, we used the Amplex Red
assay [33] to confirm and quantify the observed choles-
terol accumulations. The experiments revealed a signi-
ficantly increased cholesterol content in mutNPC1 cells in
comparison to wtNPC1 cells (Figure 5G) (fibroblasts:
mutNPC1: 13.7 ± 0.5 μg vs. wtNPC1: 7.3 ± 0.3 μg; iPSCs:
mutNPC1: 11.6 ± 0.6 μg vs. wtNPC1: 8.9 ± 0.7 μg; neural
progenitor cells: mutNPC1: 23.6 ± 0.9 μg vs. wtNPC1:
14.2 ± 1.6 μg).
Discussion
In this study we aimed to reprogram fibroblasts origina-
ting from a NPC1 patient with an early-infantile form ofrogenitor cells. Cholesterol accumulation is one of the hallmarks of
r diagnostics, where fibroblasts of NPC1 patients with a “classic”
in contrast to fibroblasts of an unaffected individual (B). These
F) derived from mutNPC1 and wtNPC1 fibroblasts. (scale bar = 100 μm).
PCs revealed elevated cholesterol levels in mutNPC1 cell lines (black bars)
between the cell lines but the relative proportion was comparable.
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Oct4, Klf4, Sox2, and c-Myc in combination with GFP.
These factors have been described previously to be effi-
cient in generating hiPSCs [34]. The retroviral particles
used in this study were successfully used to reprogram
skin fibroblasts of Parkinsons disease into hiPSCs [32].
HiPS colonies were chosen based on an absent GFP-
signal indicating a silenced expression of transcription
factors [35] and were subcultured to stable hiPSC lines.
The obtained mutNPC1 and wtNPC1 hiPSC lines were
characterized by their ES-cell like morphology, the ex-
pression of alkaline phosphatase, and the pluripotency
markers Nanog, Oct4, SSEA3, SSEA4, Tra-1-60, Tra-1-
81. A comparable expression of Tra-1-81 was reported
for NPC1 knock-down and control ES cells [36]. How-
ever, comparative analyses of additional pluripotency
markers were not performed in this study. We found no
obvious differences between mutNPC1 and wtNPC1
cells in pluripotency marker expression. These results
are in accordance with other studies dealing with
patient-specific induced pluripotent stem cells in a va-
riety of other diseases [9]. However, to our knowledge
this is the first study describing the expression of
pluripotency markers SSEA3, SSEA4, and Tra-1-60 in
pluripotent cells harboring disease-causing mutations in
the NPC1 gene. In addition, the widely known risk of
chromosomal abnormalities, potentially occurring dur-
ing iPS generation and expansion [37], did not arise in
our cell lines as proved by karyotyping. The spontaneous
differentiation by embryoid body (EB) formation [38]
into cells of all three germ layers and the induction of
teratomas in immunodeficient mice [39] further demon-
strated the pluripotent state of the mutNPC1 and
wtNPC1 hiPSCs.
We further differentiated the hiPSCs into neural pro-
genitor cells to generate a suitable in vitro disease
model. So far, two human cellular neural models based
on NPC1-knockdown have been reported. These include
SH-SY5Y neuroblastoma cells [40] and human embry-
onic stem cells [36], which resemble the phenotype only
in some aspects of the NPC1 disease. Therefore, they are
not an appropriate model to analyze the influence of
specific mutations in a patient-specific (epi)genetic back-
ground. Here, we generated homogenous neural pro-
genitor cells based on mutNPC1 and wtNPC1 hiPSCs,
which were positive for neural markers Nestin and Sox2
[41]. In contrast, Ordonez et al. [36] obtained a homo-
genous population of neural stem cells from control
hESCs but not from NPC1 knock-down hESCs. The au-
thors speculate that these findings might be based on
the genetic background of the cells [36].
Our differentiated neural progenitor cells expressed the
neuronal markers MAP2 and Tuj1. We did not observe
obvious morphological differences between mutNPC1 andwtNPC1 neuronal cells. In contrast, distortion of neuronal
shape and extensive growth of ectopic neurites have been
reported for multipotent adult stem cells (MASCs) de-
rived cells [30]. However, a further detailed analysis of our
neural progenitor cells and derived neuronal cells will be
performed to analyze changed morphology of neuronal
cells and perturbances of proliferation, described for mur-
ine neural stem cells [42]. In a first set of experiments, we
demonstrated the differentiation of neural progenitor cells
into functional neuronal cells by means of patch clamp re-
cordings. We observed voltage dependent Na+ and K+
channels, where inward currents were blocked by TTX.
Spontaneous action potentials and postsynaptic currents
could only be observed in cells differentiated for 7–8
weeks, indicating the maturation time of human neural
progenitor cells to functional neurons, as described for
interneurons derived from hiPSCs [43,44]. The here re-
corded spontaneous postsynaptic currents displayed dif-
ferent amplitudes and the time constants of the current
decay could be fitted with mono-exponential or bi-
exponential functions. The differences between the time
constants may indicate different types of synaptic input,
where currents with small amplitudes and fast mono-
exponential decay suggest excitatory and events with lar-
ger amplitudes and slow bi-exponential decay suggest in-
hibitory input [45,46]. These preliminary results indicate
that the differentiated cells are able to build up chemical
synapses. This is of special interest as recent studies de-
scribed disturbed transmitter release in NPC1 deficient
mice, where a higher rate of glutamate release was ob-
served leading to higher frequency of excitatory postsyn-
aptic currents [47]. Thus, our cells provide a platform to
study such alterations in synaptic transmission in human
neuronal cells gained from different individuals. Ulti-
mately, these results demonstrate a maturation into func-
tional neuronal cells, where future studies will focus on
the nature of the expressed voltage and ligand gated ion
channels in mutNPC1 and wtNPC1 neuronal cells.
Our neural progenitor cells were analyzed regarding
their impaired cholesterol trafficking by Filipin. It
visualizes free cholesterol and is routinely used for hu-
man dermal fibroblasts in the diagnostics of the NPC1
disease [20]. We found clear cholesterol accumulation in
mutNPC1 fibroblasts, hiPSCs, and derived neural pro-
genitor cells. In contrast, such an accumulation was not
observed in the fibroblasts, hiPSCs, or neural progenitor
cells of the wtNPC1 counterpart. The accumulation pat-
tern of cholesterol in the herein described cells was
comparable to accumulations described in a NPC1
knock-down mouse model [48], and SH-SY5Y neuro-
blastoma cells [40]. Recently, a neural model based on
multipotent adult stem cells was described [30]. The
neural differentiated progeny of these cells, demons-
trated a comparable accumulation of cholesterol, where
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sages (<3 passages) of fibroblasts, potentially limiting its
use with characterized cell lines from cell repositories.
Finally, we used the Amplex Red assay to confirm and
quantify the observed cholesterol accumulations in our
cells. These experiments revealed significantly increased
cholesterol content in mutNPC1 cells in comparison to
wtNPC1 cells, which was conserved in fibroblasts, hiPSCs,
and derived neural progenitor cells. To our knowledge this
is the first analysis of cholesterol distribution using Filipin
staining and cholesterol quantification in hiPSCs and
neural progenitor cells derived from human NPC1 defi-
cient fibroblasts.
Conclusion
In this study we generated, for the first time, induced
pluripotent stem cells derived from fibroblasts of a
NPC1 patient. The cells demonstrated an accumulation
of cholesterol, resembling the phenotype of NPC1 defi-
cient cells, and can provide an in vitro model of NPC1.
We are convinced that the here reported hiPSCs and the
derived neural progenitor cells are an excellent model to
study the influence of the specific mutation on the
phenotype, e.g. consequences of a misfolded NPC1 pro-
tein. Moreover, the cells provide the opportunity to
analyze the consequences of a NPC1 mutation on the
patient-specific (epi)genetic background, and will thus
serve to elucidate further the pathogenic mechanisms of
this fatal lysosomal storage disorder.
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